EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials

Luis Ortega-Paz, Azita H Talasaz, Parham Sadeghipour, Sina Rashedi, Jean M Connors, Dominick J Angiolillo, Larisa H Cavallari, David Jimenez, Gabriela Bastidas, Elizabeth Lorenzi, Lindsay R Berry, Thomas Hills und 14 weitere

Thrombosis Research · 2025

DOI: 10.1016/j.thromres.2025.109484 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Thrombosis Research, 2025. Verfasst von Luis Ortega-Paz und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, COVID-19 Drug Treatment, COVID-19. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Statins may impact COVID-19 outcomes through lipid-mediated and lipid-independent pathways. However, the clinical impact of statin therapy among hospitalized patients with COVID-19 remains unclear due to the limited power of existing randomized controlled trials (RCTs). METHODS: A systematic search of PubMed, Embase, and clinicaltrials.gov was conducted through July 17th, 2024. RCTs were included if they compared statin therapy to control (placebo or standard care) in hospitalized COVID-19 patients and enrolled at least 250 randomized participants. Studies with co-treatment were considered in sensitivity analyses. The primary effectiveness outcome was 30-day all-cause death. The main safety outcomes were myopathy and rise in liver enzymes. RESULTS: Three RCTs were included in the main analysis (3882 statin-naive patients, 33.7 % female, average follow-up duration 37 days). Compared with control, statin therapy was associated with reduced all-cause death (20.9 % vs. 23.8 %; odds ratio [OR]: 0.82, 95 % confidence interval [CI] 0.70-0.96; P = 0.01), with a small but significant increase in myopathy (0.6 % vs. 0 %; risk difference: 0.00, 95 % CI -0.00; 0.01), and no significant difference in liver enzyme abnormalities (1.0 % vs. 1.4 %; OR 1.00, 95 % CI: 0.25-3.99). A sensitivity analysis including two additional RCTs that included randomized co-treatments yielded similar findings. There were no significant interactions for effectiveness by disease severity (critically vs. non-critically ill, P = 0.38) or sex (males vs. females, P = 0.83). CONCLUSION: Among hospitalized patients with COVID-19, statin therapy was associated with a significant reduction in 30-day all-cause death compared with control and exhibited an excellent safety profile. STUDY REGISTRATION: This study is registered in PROSPERO (CRD42023478764).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCOVID-19 Drug TreatmentCOVID-19HumansRandomized Controlled Trials as TopicHospitalizationSARS-CoV-2FemaleMaleMuscular DiseasesTreatment Outcome

Stichwörter der Autor:innen

Coronavirus disease 2019DeathLipidStatinVenous thromboembolism

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Long Island University, New York, NY, USA; Department of Pharmacy, New York-Presbyterian Hospital/Columbia University Irv…
  • Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran; Clinical Trial Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical S…
  • Cardiovascular Medicine Division, Brigham and Women's Hospital, Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, USA.
  • Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, FL, USA.

Zitieren

APA

Ortega-Paz, L., Talasaz, A. H., Sadeghipour, P., Rashedi, S., Connors, J. M., Angiolillo, D. J., Cavallari, L. H., Jimenez, D., Bastidas, G., Lorenzi, E., Berry, L. R., Hills, T., McAuley, D. F., Shah, T., Lansky, A. J., Deepti, S., Gaitán-Duarte, H. G., Potpara, T. S., Galli, M., …, & Bikdeli, B. (2025). Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials. Thrombosis Research. https://doi.org/10.1016/j.thromres.2025.109484

Vancouver

Ortega-Paz L, Talasaz AH, Sadeghipour P, Rashedi S, Connors JM, Angiolillo DJ, et al. Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials. Thrombosis Research. 2025. doi:10.1016/j.thromres.2025.109484

BibTeX
@article{OrtegaPaz2025,
  author = {Ortega-Paz, Luis and Talasaz, Azita H and Sadeghipour, Parham and Rashedi, Sina and Connors, Jean M and Angiolillo, Dominick J and Cavallari, Larisa H and Jimenez, David and Bastidas, Gabriela and Lorenzi, Elizabeth and Berry, Lindsay R and Hills, Thomas and McAuley, Daniel Francis and Shah, Tayyab and Lansky, Alexandra J and Deepti, Siddharthan and Gaitán-Duarte, Hernando Guillermo and Potpara, Tatjana S and Galli, Mattia and Dixon, Dave L and Piazza, Gregory and Lip, Gregory Y H and Mehran, Roxana and Libby, Peter and Krumholz, Harlan M and Bikdeli, Behnood},
  title = {Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials},
  journal = {Thrombosis Research},
  year = {2025},
  doi = {10.1016/j.thromres.2025.109484}
}
Kostenlos starten →